Press Releases

Patient navigators serve as personal health care guides, maintaining one-on-one relationships with patients and their families. Roswell Park Cancer Institute has expanded its breast cancer navigation program due, in part, to a new contract from Gov. Andrew Cuomo’s Breast Cancer Patient Navigation Project.

Tactiva Therapeutics LLC, a new biotech company spun off from Roswell Park Comprehensive Cancer Center, will create jobs as it develops some of the most promising concepts in the burgeoning field of cancer immunotherapy and accelerates the timeline for getting beneficial therapies to patients.

More than 1 in 4 adults and nearly 1 in 10 youth use tobacco, according to findings from the Population Assessment of Tobacco and Health (PATH) Study, published online ahead of print in the New England Journal of Medicine. The PATH Study, established in 2011 through collaboration between the National Institutes of Health’s National Institute on Drug Abuse and the U.S. Food and Drug Administration’s Center for Tobacco Products, is a uniquely large, nationally representative longitudinal study designed to examine tobacco use behaviors and health among the U.S. population over multiple years of follow-up. The PATH Study is being conducted by Westat of Rockville, Md., with Roswell Park Comprehensive Cancer Center as the scientific lead.

Metastasis, or spread of a tumor from the site of origin to additional organs, causes >90% of cancer-related deaths, but our understanding of the molecular mechanisms behind metastasis remains limited.

Roswell Park Cancer Institute faculty members are among the leaders who helped to plan the 2017 Gastrointestinal Cancer Symposium, a three-day specialized oncology meeting that continues through Jan. 21 in San Francisco, CA. Gastrointestinal cancers include cancers of the pancreas, small bowel, hepatobiliary tract, colon, rectum, esophagus and stomach.

New York Governor Andrew Cuomo’s plan to regulate and tax vapor products used in electronic cigarettes is an important step in protecting youth and nonusers from possible detrimental impacts, say experts from Roswell Park Comprehensive Cancer Center and Tobacco-Free Western New York (TFWNY).

Today, The Ride For Roswell presented by West Herr Automotive Group launched registration for its 2017 event, taking place on Saturday, June 24. Community members of all ages and cycling experience are invited to “choose your route to a cure” by signing up to ride or volunteer at RideForRoswell.org.

The architecture firm that brought the Scott Bieler Clinical Sciences Center to life on the Roswell Park Comprehensive Cancer Center campus has been honored for its efforts. FXFOWLE received the Buffalo/WNY Architecture Award at the 2016 awards gala of AIA Buffalo/WNY, the regional chapter of the American Institute of Architects. The award, recognizing the firm’s work on the 11-story clinical care facility, is the highest honor conferred by the chapter.

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of scientists led by Irwin Gelman, PhD , Professor of Oncology in the Department of Cancer Genetics at Roswell Park Cancer Institute, has identified an 11-gene signature unique to advanced recurrent prostate cancer that they believe will help to identify these aggressive and potentially fatal prostate cancers sooner. The findings have been published online ahead of print in the journal Oncotarget.